These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 28479604)
1. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Kang XJ; Wang HY; Peng HG; Chen BF; Zhang WY; Wu AH; Xu Q; Huang YZ Acta Pharmacol Sin; 2017 Jun; 38(6):885-896. PubMed ID: 28479604 [TBL] [Abstract][Full Text] [Related]
2. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
3. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice. Jin Q; Zhou X; Niu X; Ping C; Dong X; Duan D; Wang R; Chen Y; Pan F; Yang F; Yang X; Zhang G; Wang R; Zhang S; Ren G Colloids Surf B Biointerfaces; 2024 Sep; 241():113992. PubMed ID: 38833960 [TBL] [Abstract][Full Text] [Related]
5. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857 [TBL] [Abstract][Full Text] [Related]
6. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells. Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952 [TBL] [Abstract][Full Text] [Related]
7. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug. Ling L; Ismail M; Du Y; Yao C; Li X Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133 [TBL] [Abstract][Full Text] [Related]
8. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect. Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044 [TBL] [Abstract][Full Text] [Related]
9. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer. Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609 [TBL] [Abstract][Full Text] [Related]
11. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance. Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761 [TBL] [Abstract][Full Text] [Related]
12. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells. Shen Q; Qiu L J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors. Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479 [TBL] [Abstract][Full Text] [Related]
14. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo. Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells. Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042 [TBL] [Abstract][Full Text] [Related]
16. Chitosan-alginate BSA-gel-capsules for local chemotherapy against drug-resistant breast cancer. Shen H; Li F; Wang D; Yang Z; Yao C; Ye Y; Wang X Drug Des Devel Ther; 2018; 12():921-934. PubMed ID: 29719378 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells. Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844 [TBL] [Abstract][Full Text] [Related]
18. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132 [TBL] [Abstract][Full Text] [Related]
19. Endosomal escape by photo-activated fusion of liposomes containing a malachite green derivative: a novel class of photoresponsive liposomes for drug delivery vehicles. Hayashi K; Watanabe M; Iwasaki T; Shudou M; Uda RM Photochem Photobiol Sci; 2019 Jun; 18(6):1471-1478. PubMed ID: 30964475 [TBL] [Abstract][Full Text] [Related]
20. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]